Interesting...Wall Street trying to figure out how to hit the "moving target" of where to invest with health care as related to Oncology...that explains some recent inquiries....hope they have some good software available to crunch the information with some sophisticated Business Intelligence software doing the drill down mining...BD
Tomorrow night, at 9 p.m. Eastern, American Society of Clinical Oncology is going to release the results of thousands of cancer studies that will be presented at the group’s big annual meeting. At least a few of those are likely to be market-moving, especially the ones that involve small biotechs whose future rests on a single cancer drug.
But the trick is finding the market-moving needles in a haystack of data — and doing it before the markets open Friday morning. Of course, some analysts aren’t waiting for the abstracts to make bets about what the data will hold. Morgan Stanley analyst Steven Harr on Monday lowered his rating on ImClone, which makes the cancer drug Erbitux. The company’s stock fell more than 7% Monday, before recovering a bit yesterday.
Health Blog : Wall Street Drug Analysts to Pull All-Nighter Tomorrow
0 comments :
Post a Comment